Opyl Ltd. (AU:OPL) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Opyl Limited, an AI-focused clinical trial design company, has announced a joint venture with the US and UK-based Xco consortium to market and sell its TrialKey products in Europe, the Middle East, Africa, and North America. The deal includes a due diligence period, a cash payment to Opyl for licensing, a planned capital raise for the JV, and a revenue-sharing agreement. Executive Chairman Saurabh Jain views the partnership as a strategic move to scale the company’s global presence and drive growth.
For further insights into AU:OPL stock, check out TipRanks’ Stock Analysis page.